ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ PHÁC ĐỒ GEMCITABIN- CISPLATIN TRÊN BỆNH NHÂN UNG THƯ ĐƯỜNG NIỆU GIAI ĐOẠN TIẾN TRIỂN TẠI BỆNH VIỆN K

Abstract

Objective: To describe some clinical characteristics, subclinical characteristics and treatment results of the gemcitabin-cisplatin regimen on patients with advanced urothelial cancer at K hospital. Patients and research methods: The study describes 32 patients with advanced urothelial cancer who were treated with gemcitabine-cisplatin regimen at K Hospital from 4/2021 to 11/2023. Results:  The common age is ≥ 60 years olds, the mean age is 61,25±9,9 years. The proportion of men accounts for 84.4%. The rate of patients with bladder cancer is 50%. The response rate was 62.5%. Median progression-free survival time was 5.6 months (4.9-6.3). Performance status PS=2 was significant adverse prognostic implications to reduce median PFS (P=0,01). Side effects on the hematologic are mainly. The toxicity of the gem-cis regimen was mild and acceptable. The toxicity of the gem-cis regimen was mild and acceptable. Conclusion: Gemcitabine-Cisplatin regimen for treating patients with advanced urothelial cancer has a high response rate. Performance status PS=2 was significant adverse prognostic implications to reduce median PFS (P=0,01). Gem-cis regimen is safe with mild and controllable side effects.